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Abstract
Introduction: S100 protein and GFAP expression in pituitary adenomas tumour cells is not well known; few correlations with other 
prognostic or therapeutic factors have previously been reported in pituitary adenomas. We aim to elucidate their involvement in the 
pathogenesis of pituitary adenomas and to establish the correlation of their expression with different growth factors and growth factor 
receptors known to have a prognostic and/or therapeutic role. 
Material and methods: Sixty-one cases of pituitary adenomas were immunohistochemically assessed for the expression of GFAP and S100 
protein in both tumour cells and FS cells, in close relationship with hormone profile, and correlated with vascular endothelial growth 
factor (VEGF) and epidermal growth factor receptor (EGFR) expression, previously studied by our team. 
Results: GFAP and S100 protein were expressed both in tumour cells and FS cells. Differences between morphology, distribution, and den-
sity of GFAP+ FS cells and S100+ FS cells were observed according to the hormone profile of pituitary adenomas. GFAP and S100 protein 
expression in tumour cells was significantly related to hormone profile of pituitary adenomas and also with VEGF and EGFR expression. 
Conclusions: GFAP and S100 protein expressions in tumour cells from pituitary adenomas are influenced by hormone profile. Our re-
sults support the presence of two molecular subtypes of FS cells GFAP+/VEGF+/S100 respectively and another one that is GFAP-/S100+/ 
/EGFR+ simultaneously with the classical variant GFAP+/S100+. It is possible that S100+/EGFR+ pituitary adenomas represent a group 
of pituitary adenomas with an aggressive behaviour and a high ability of invasion and recurrence.  (Endokrynol Pol 2017; 68 (4): 380–389)
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Streszczenie
Wstęp: Ekspresja białka S100 i kwaśnego białka włókienkowego gleju (GFAP, glial fibrillary acid protein) w gruczolakach przysadki móz­
gowej nie została dobrze poznana. Dostępne są nieliczne publikacje dotyczące korelacji tych cząsteczek z innymi czynnikami progno-
stycznymi lub terapeutycznymi w gruczolakach przysadki. Celem niniejszej pracy jest wyjaśnienie udziału tych białek w patogenezie 
gruczolaków przysadki i ustalenie korelacji między ich ekspresją a różnymi czynnikami wzrostu lub receptorami czynników wzrostu 
o znanej wartości prognostycznej i/lub terapeutycznej. 
Materiał i metody: Sześćdziesiąt sześć przypadków gruczolaka przysadki zbadano metodami immunohistochemicznymi w celu oceny 
ekspresji białek GFAP i S100 zarówno w komórkach guza, jak i w komórkach pęcherzykowo­gwiaździstych (FS, folliculo­stellate cells) 
oraz przeanalizowania uzyskanych wyników w ścisłej zależności z profilami hormonalnymi gruczolaków i w korelacji z ekspresją czyn-
nika wzrostu śródbłonka naczyniowego (VEGF, vascular endothelial growth factor) i receptora naskórkowego czynnika wzrostu (EGFR, 
epidermal growth factor receptor), ocenianych w badaniu przeprowadzonym wcześniej przez nasz zespół. 
Wyniki: Ekspresję białek GFAP i S100 stwierdzono zarówno w komórkach guza, jak i w komórkach FS. Zaobserwowano różnice pod 
względem morfologii, rozkładu i gęstości komórek FS z dodatnią ekspresją białek GFAP i S100 (GFAP+FS i S100+FS) odpowiadające 
profilowi hormonalnemu gruczolaków przysadki. Ekspresja białek GFAP i S100 w komórkach guza była istotnie związana z profilem 
hormonalnym gruczolaków przysadki, a także z ekspresją VEGF i EGFR. 
Wnioski: Ekspresja białek GFAP i S100 w komórkach gruczolaka przysadki zależy od profilu hormonalnego guza. Uzyskane w badaniu 
wyniki potwierdzają obecność dwóch podtypów molekularnych komórek FS GFAP+/VEGF+/S100 oraz jednego typu GFAP–/S100+/ 
/EGFR+ występujących jednocześnie z klasycznym wariantem GFAP+/S100+. Możliwe, że gruczolaki przysadki z ekspresją S100+/ 
/EGFR+ należą do grupy tych nowotworów cechujących się agresywnością i dużą zdolnością do naciekania i nawrotów.  (Endokrynol 
Pol 2017; 68 (4): 380–389)
Słowa kluczowe: białko S10, GFAP, komórki pęcherzykowo-gwiaździste, gruczolaki przysadki
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Introduction
The normal pituitary gland is known to express a wide 
panel of immunohistochemical markers with a great 
heterogeneity of expression, which is region dependant. 
As has been experimentally demonstrated in specimens 
taken from the pars intermedia, ACTH type cells mostly 
express cytokeratins and vimentin [1]. All hormone-
producing cells are positive for cytokeratins, it appears 
that the folliculo-stellate cells from the adenohypo-
physis are selectively stained with CK19, while other 
regions contain EMA, sialomucin, and Leu­7­positive 
cells [1]. In a similar manner to the normal pituitary, 
adenomas show a differential expression of immuno-
histochemical markers. It has been demonstrated that 
most adenomas express cytokeratins [1]. In the same 
study, Kasper et al. [1] showed that co­expression of 
vimentin and neurofilament protein is rare in pituitary 
adenomas. Also, unlike the normal hypophysis, pitui-
tary adenomas are negative for EMA and sialomucin 
but present an increased Leu­7 expression, which is 
encountered in the GH type and prolactin type of 
pituitary adenomas. Protein S100 and the glial fibril-
lary acidic protein (GFAP) in pituitary adenomas have 
been little studied. It appears that folliculo-stellate cells 
are positive for these two markers, most probably due 
to their glial origin [2]. It has been demonstrated that 
S100 protein is also expressed by the epithelial cells that 
line Rathke cysts and by some cells located in the pars 
tuberalis [2]. Moreover, a limited number of cells from 
Rathke cysts seem to co-express cytokeratins, protein 
S100, and GFAP, an aspect that is sometimes related to 
neoplastic changes [2]. Carcinogenesis in the pituitary 
gland seems to be enhanced by TNF­alpha and IL­6, 
as has been shown in invasive pituitary adenomas [3]. 
Other differential expressions have been noticed in 
ACTH type adenomas. It appears that these tumours 
present a diffuse positive reaction for CK20 and CK7, 
while TTF­1 expression was considered insignificant [4]. 
Only a few scattered literature data are found regarding 
the expression of protein S100 and GFAP in pituitary 
adenomas, but lot of information is available regarding 
their expression in tumours of the neurohypophysis 
[5–8]. Their expression in the pituitary tissue is limited 
to their description in the folliculo-stellate cells as well 
as in relation to the stem cells of the anterior pituitary 
gland. Folliculo-stellate cells are known to be contro-
versial histological and pathological entities in both 
humans and mammals [9–11]. Folliculo­stellate cells 
have been reported as reactive players in pituitary 
adenomas [9] and possess a heterogenous S100 and 
GFAP expression, thus leading to the classification of 
subgroups with different phenotypes. It appears that, 
besides their role as sustentacular cells of the adeno-
hypophysis, folliculo-stellate cells are characterised by 
a great plasticity and possess the ability to modulate 
the hypothalamo-hypophyseal-adrenal axis in spe-
cial conditions [11, 12]. In spindle cell oncocytoma, 
a discussed pathologic entity, which seems to originate 
from folliculo-stellate cells, tumour cells are positive 
for S100 but, surprisingly, negative for GFAP [13–15]. 
Unlike spindle cell oncocytomas and adenomas of the 
anterior hypophysis, the adamantinomatous type of 
craniopharyngioma exhibits a positive GFAP reaction, 
while other tumour types appear to be negative for both 
S100 protein and GFAP but positive for TTF­1 [16, 17]. 
GFAP, a marker of the neuroendocrine system, is 
strongly expressed in the neurohypophysis, namely by 
the granular cells and by the filament containing cells 
belonging to the choristoma, probably due to the fact 
that both cell types emerge from astrocytes [18]. S100 
protein and GFAP expression in the tumour cells of 
pituitary adenomas is less studied, and the implication 
of these factors in the evolution and pathogenesis of 
pituitary adenomas has little been correlated with other 
prognostic or therapeutic factors that have previously 
been studied in pituitary adenomas. Besides protein 
S100 and GFAP, the neuroglial antigen 2 (NG­2) is an-
other controversial marker in tumours of the pituitary 
gland. Normally, NG­2 is expressed by oligodendro-
cytes progenitors, pericytes, and tumour cells [19]. In 
pathological situations, this marker is exhibited by all 
tumour types of the adenohypophysis except for the 
ACTH type [19]. It has also been demonstrated that 
NG­2 modulates the prolactin type and the GH type 
adenomas through enhancement of cell adhesion but 
without influencing proliferation [19]. Previous data 
available in literature regarding pituitary pathology 
shows that a molecular mapping of the normal hypo-
physis, and of the various tumour types that emerge 
from it, serves as a useful tool for differential diagnosis 
and for the diagnosis of ectopic hormone-producing 
tissue and of metastases [20]. Based on these scattered 
literature data, the research that has been led in the 
present study has been initiated with the purpose of 
elucidating the implication of protein S100 and GFAP 
in the evolution and prognosis of pituitary adenomas, 
and to establish the correlation of their expression with 
different growth factors known as prognostic and/or 
therapeutic markers in several types of tumours but, 
also, less investigated in pituitary adenomas.
Material and methods 
For our retrospective study, we selected 61 paraffin­
embedded specimens of pituitary adenomas based on 
accurate criteria regarding the pre-analytical stages, 
which included fixation, paraffin embedding proce-
382
PR
A
C
E 
O
RY
G
IN
A
LN
E
GFAP and S100 protein in pituitary adenomas Anca Maria Cimpean et al.
dures, and three-micrometer serial section perfor-
mance. Histopathologic re­evaluation was performed 
by three experienced pathologists who examined the 
haematoxylin and eosin-stained slides and selected 
six additional sections from each case to establish 
the hormone profile of pituitary adenomas, growth 
hormone (GH), prolactin (PRL), adrenocorticotropic 
hormone (ACTH), thyroid stimulating hormone (TSH), 
folliculo­stimulating hormone (FSH), and luteinising 
hormone (LH). Immunohistochemical procedures were 
performed to highlight all six pituitary hormones, i.e. 
growth hormone (GH, polyclonal rabbit anti­human, 
dilution 1 : 300), prolactin (PRL, polyclonal rabbit anti­
human, dilution 1 : 250), adrenocorticotropin (ACTH, 
monoclonal mouse anti­human, clone 02A3, dilution 
1 : 50), thyroid stimulating hormone (TSH, monoclonal 
mouse anti­human, clone 0042, dilution 1 : 50), lutein-
izing hormone (LH, monoclonal mouse anti­human, 
clone C93, dilution 1 : 50), and follicle stimulating hor-
mone (FSH, monoclonal mouse anti­human, clone C10, 
dilution 1 : 50). All primary antibodies were supplied by 
Dako Cytomation, Carpinteria, USA. 
Glial fibrillary acidic protein (monoclonal mouse 
anti human, clone GA5, ready to use, Novocastra) and 
S100 protein (rabbit polyclonal, Novocastra) were also 
performed by immunohistochemistry. All steps of im-
munohistochemical procedures were performed in an 
automated manner by using Bond Max Autostainer 
(Leica, Microsystems), having well standardised proto-
cols specific for each antibody included in the present 
study. 
Microscopic evaluation was made by two inde-
pendent observers using a Nikon Eclipse E600 micro-
scope (Nikon Corporation Japan). The images were 
captured and processed using a Lucia G system. For 
the evaluation of the hormone profile, more than 
10% positive cells was considered a secreting tumour. 
Tumours presenting an increased GH, PRL expression 
were considered as a mamosomatotroph. GFAP and 
S100 protein were evaluated both in tumour cells and 
folliculostellate cells of the pituitary adenomas. Their 
expression was correlated with hormone profile and 
epidermal growth factor receptor (EGFR) previously 
studied on the same cases, and considering a poten-
tial therapeutic target for several tumours. Statistical 
analysis was made using the SPSS system version 17. 
The statistical methods included correlation tests such 
as Pearson, Kendall, and Spearman. The correlations 
were considered statistically significant if the p value 
was less than 0.05. A total correlation was considered 
when all three test groups presented significant val-
ues, and a partial correlation was considered when 
two out of three correlation tests presented statistical 
significance.
Results
GFAP expression was immunohistochemically quan-
tified in the normal pituitary gland and in pituitary 
adenomas. GFAP heterogeneous expression correlated 
with the cell types and its distribution has been dem-
onstrated. Initially, GFAP expression was described in 
the normal pituitary gland. Regarding the expression 
pattern, we encountered a cytoplasmic distribution of 
GFAP and a cytoplasmic combined with a membranar 
pattern in both endocrine and folliculo-stellate cells (FS) 
(Fig. 1a, b, c). In the acidophilic cells, GFAP was weakly 
expressed in the cytoplasm rarely with a membranar 
pattern. Inserted amongst these cell types, intensely 
positive cells were observed, with a chromophobe and 
basophilic morphology. FS were distributed amongst 
the endocrine cells but closely related to and surround-
ing capillary vessels and, as expected, had a different 
morphology with rare and short expansions that were 
strongly interconnected with the wall of the capillary 
vessel. FS cells were discontinuously distributed around 
the fenestrated capillary vessels, the contact between 
these cells and the capillary wall being made only 
through the expansions of the FS cells (Fig. 1d). FS cells 
density was relatively low, 2–4 cells/capillary vessel be-
ing observed. A particular aspect was observed in the 
area of the tuberal portion of the pituitary gland where 
the cells that lined the pseudofollicular structures were 
intensely positive for GFAP (Fig. 1e). Pituitary adeno-
mas were characterised by a higher GFAP expression, 
compared with normal pituitary gland, but with the 
same distribution both in the tumour endocrine cells 
and in the FS cells, respectively. 
From the total number of cases included in the study, 
43.33% had a positive reaction for GFAP in tumour 
cells with low or moderate expression, with a strictly 
cytoplasmic location. The intensity of GFAP expression 
in FS cells was similar to that found in FS cells from the 
normal pituitary gland, but their number increased 
substantially compared with normal pituitary gland.
The distribution of GFAP­positive FS cells (GFAP + 
FS cells) was dependent on the hormone profile of the 
adenomas included in the study. Thus, in the adenomas 
with a GH or GH­PRL combined profile, the FS cells had 
a low density, being inserted amongst the tumour cells 
(Fig. 2a) that presented a low or moderate positive reaction 
for the same marker (Fig. 2b). In chromophobe cell adeno-
mas, tumour cells were negative for GFAP, the intensity 
and the density of GFAP +FS cells being high. For ACTH­
secreting adenomas, GFAP expression was restricted to the 
FS cells that presented a particular distribution, tumour 
cells being negative. An increase in the density of GFAP 
+ FS cells was observed compared with normal pituitary 
gland. Their distribution was also specific; namely, they 
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The presence of GFAP+ FS cells in the normal pitui-
tary tissue and in pituitary adenomas revealed a mor-
phological heterogeneity that was dependent not only on 
the normal or the tumour status but also on the hormone 
profile of pituitary adenomas. Thus, in the normal pitui-
tary tissue, GFAP+ FS cells had an elongated cell body 
and presented short and rare expansions, interposed 
amongst endocrine cells or attached to the capillary wall 
(Fig. 2e, inset) compared with GH secreting pituitary 
adenomas, where GFAP+ FS cells presented an irregular 
body, mostly with a triangular aspect, with rare expan-
sions, strongly attached to the adenoma tumour cells. 
Starting from the microscopic observation of the 
morphological heterogeneity of the GFAP+ FS cells, 
we continued the study with the assessment of the 
correlation between GFAP expression and the hormone 
profile of pituitary adenomas, to identify the potential 
were grouped around the blood vessels, with a tendency 
to form a relatively continuous layer around the capillary 
vessels (Fig. 2c). ACTH­secreting pituitary adenomas 
were characterised by the presence of vascular spaces, 
apparently not lined by endothelial cells, with the wall 
composed of tumour cells and palisading GFAP + FS cells 
(Fig. 2d). GFAP + FS cells belonging to ACTH­secreting 
adenomas presented an oval, elongated cell body that 
was inserted amongst tumour cells, with a characteristic 
“palisade-like” distribution, and which had the tendency 
to give sprouting expansions only from the cell pole op-
posite to the vascular or pseudo-vascular lumen. 
The highest density of GFAP + FS cells was observed 
in plurihormonal pituitary adenomas, predominantly in 
the papillary type. GFAP+ FS cells formed in this case a 
well-organised network though the interrelation that they 
established with their cytoplasmic expansions (Fig. 2e).
Figure 1. GFAP expression pattern in the normal pituitary gland. The heterogeneity of expression between the nests of endocrine cells 
(a), followed by a cytoplasmic expression pattern or cytoplasmic and membranous combined (b). In the stellate follicular cells (FS), the 
expression was intense and homogenous (c). Stellate follicular cells surrounding the capillary vessels, with their expansions attached to 
the wall of the blood vessel. Note the relatively low density of FS cells on the circumference of the capillary vessel (d). Pseudofollicular 
structures lined by GFAP positive cells, together with stellate follicular cells that are located around the pseudofollicular structures from 
the intermediate part of the pituitary gland (e)
Rycina 1. Ekspresja GFAP w prawidłowej przysadce. Zróżnicowanie ekspresji między gniazdami komórek endokrynnych (a); występuje 
ekspresja cytoplazmatyczna lub cytoplazmatyczna i błonowa (b). W komórkach pęcherzykowato-gwiaździstych (FS, stellate follicular) 
ekspresja jest intensywna i jednorodna (c). Komórki pęcherzykowo-gwiaździste otaczające naczynia włosowate; ekspansja związana 
ze ścianą naczynia krwionośnego. Należy zwrócić uwagę na stosunkowo małą gęstość komórek FS wokół naczynia włosowatego (d). 
Rzekomopęcherzykowe struktury wysłane komórkami GFAP-dodatnimi oraz komórki pęcherzykowato-gwiaździste rozmieszczone wokół 
struktur rzekomopęcherzykowych w pośredniej części przysadki (e)
e
a b c
d
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Figure 2. GFAP-positive tumour cells presenting a low and moderate intensity of reaction amongst which GFAP intensely positive stellate 
follicular cells are observed (a) in a GH-secreting pituitary adenoma. The high density of FS cells, GFAP positive, in an LH-secreting 
pituitary adenoma (b). FS cells with a perivascular distribution (b) and with the tendency of forming, along with tumour cells, the wall 
that lines the pseudovascular spaces, characteristic for ACTH-secreting pituitary adenomas (c). The distribution of FS-GFAP+ cells in 
plurihormonal pituitary adenomas. Note the high density and the network-like disposition given by the interconnections between the 
numerous expansions of the FS-GFAP+ cells (d). The interposition of tumour cells between the FS-GFAP+ cell expansions and the 
wall of the capillary vessel, which suggests disruption of the blood-brain barrier (d, inset).
Rycina 2. Gruczolak przysadki wydzielający GH (a): słabo lub umiarkowanie GFAP-dodatnie komórki guza, między którymi 
widoczne są silnie GFAP-dodatnie komórki pęcherzykowato-gwiaździste. Gęsto ułożone GFAP-dodatnie komórki FS w gruczolaku 
przysadki wydzielającym LH (b). Komórki FS rozmieszczone wokół naczyń krwionośnych (b) z tendencją do formowania, wraz 
z komórkami guza, ścian tworzących przestrzenie imitujące naczynia krwionośne, co jest charakterystyczne dla gruczolaków przysadki 
wydzielających ACTH (c). Rozkład komórek FS-GFAP+ w gruczolakach plurihormonalnych. Należy zwrócić uwagę na dużą gęstość 
i sieciowy układ spowodowany połączeniami między licznymi rozrastającymi się komórkami FS-GFAP+ (d). Komórki guza znajdują 
się między rozrastającymi się komórkami FS-GFAP+ a ścianami naczyń krwionośnych, co sugeruje przerwanie bariery krew–mózg 
(d, wstawka)
a b
c d
e
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influences of the pituitary hormones on the GFAP + 
FS cell variability. Amongst all pituitary hormones, 
GH­expressing pituitary adenomas presented a significant 
but low correlation with GFAP expression (p = 0.05 for 
Pearson index), but significant for Kendall and Spear-
man indexes (Table I). A strong correlation was also 
registered between ACTH and GFAP expression, thus 
the correlation index was statistically significant, at 12 
(Table IIa, b). A low correlation was also present in that 
which considers LH (Table IIc). Regarding the other 
molecular markers included in the study, we registered 
an inversed correlation between GFAP expression and 
that of oncoprotein HER2 (p = 0.025). EGFR overex-
pression did not significantly overlap GFAP expression 
from a statistical point of view (p = 0.072). On the other 
hand, we registered a very strong correlation between 
GFAP and VEGF overexpression in pituitary adenomas 
(p = 0.0014). 
S100 protein in pituitary adenomas was also stud-
ied by using the immunohistochemical method on the 
normal pituitary gland and in pituitary adenomas. S100 
protein had a nuclear and cytoplasmic pattern, being 
positive in the FS cells but also in the endocrine cells of 
the normal pituitary gland and the adenoma ones. The 
combined nuclear/cytoplasmic pattern was observed 
in tumour cells for about 19.5% of S100­positive cases; 
GH GFAP
GH Pearson correlation 1.000 0.207
Sig. (1-tailed) – 0.55
N 61 61
GFAP Pearson correlation 0.207 1.000
Sig. (1-tailed) 0.55 –
N 61 61
GH GFAP
Kendall’s tau_b GH Correlation coefficient 1.000 0.194
Sig. (1-tailed) – 0.046
N 61 61
GFAP Correlation coefficient 0.194 1.000
Sig. (1-tailed) 0.046 –
N 61 61
Spears’man rho GH Correlation coefficient 1.000 0.218
Sig. (1-tailed) – 0.046
N 61 61
GFAP Correlation coefficient 0.218 1.000
Sig. (1-tailed) 0.046 –
N 61 61
Table I. Statistical correlation between GFAP expression and GH-secreting pituitary adenomas
Tabela I. Statystyczna korelacja między ekspresją GFAP a gruczolakami wydzielającymi GH
Table 2. Statistical correlation between GFAP expression and ACTH-secreting pituitary adenomas
Tabela 2. Statystyczna korelacja między ekspresją GFAP a gruczolakami wydzielającymi ACTH
GFAP Pearson correlation 1.000 0.276
Sig. (2-tailed) – 0.031
N 61 61
ACTH Pearson correlation 0.276 1.000
Sig. (2-tailed) 0.031 –
N 61 61
GFAP LH
GFAP Pearson correlation 1.000 0.203
Sig. (1-tailed) – 0.058
N 61 61
LH Pearson correlation 0.203 1.000
Sig. (1-tailed) 0.058 –
N 61 61
Kendall’s tau_b GFAP Correlation coefficient 1.000 0.296
Sig. (2-tailed) – 0.012
N 61 61
ACTH Correlation coefficient 0.296 1.000
Sig. (1-tailed) 0.012 –
N 61 61
Spears’man rho GFAP Correlation coefficient 1.000 0.325
Sig. (2-tailed) – 0.011
N 61 61
GFAP Correlation coefficient 0.325 1.000
Sig. (2-tailed) 0.046 –
N 61 61
a
c b
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Figure 3. The expression of protein S100 in the normal pituitary gland. Note the intense, nuclear, and cytoplasmic expression in the 
stellate follicular cells and the moderate cytoplasm-restricted expression in the endocrine cells, with an acidophilic pattern on HE and 
a low intensity in chromophobe cells (a). The variability of protein S100 expression in GH-secreting pituitary adenomas: intense, nuclear, 
and cytoplasmic (b), intense, cytoplasmic (c). Chromophobe type pituitary adenoma with chromophobe cells negative for protein S100 in 
their cytoplasm, with a focal and heterogenous expression in the nuclei of the chromophobe cells and in the cytoplasm, and the nucleus 
of FS cells inserted amongst chromophobe cells 
Rycina 3. Ekspresja białka S100 w prawidłowej przysadce. Należy zwrócić uwagę na silną ekspresję w jądrze i cytoplazmie komórek 
pęcherzykowo-gwiaździstych oraz umiarkowaną ekspresję ograniczoną do cytoplazmy w komórkach endokrynnych z wybarwieniem 
kwasochłonnym w preparatach barwionych HE i małą ekspresję w komórkach barwnikoopornych (a). Zróżnicowanie ekspresji białka S100 
w gruczolakach przysadki wydzielających GH: silna ekspresja w jądrze komórkowym i cytoplazmie, (b) silna ekspresja w cytoplazmie. 
(c) Barwnikooporny gruczolak przysadki z komórkami barwnikoopornymi niewykazującymi cytoplazmatycznej ekspresji białka S100; 
widoczna ogniskowa, heterogenna ekspresja jądrowa w komórkach barwnikoopornych oraz ekspresja cytoplazmatyczna i jądrowa 
w komórkach FS znajdującymi się między komórkami barwnikoopornymi
387
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the remaining cases presenting a cytoplasmic-restricted 
expression. 
The percentage of S100­positive cases was 66.12% 
from the total number of cases. Amongst these, 39.02% 
presented a compact growth pattern, 39.04% were of 
papillary type, 9.75% presented a trabecular growth pat-
tern, 4.87% spindle­shaped, and 7.31% were of alveolar 
type. Papillary type pituitary adenomas registered the 
highest intensity of S100 protein expression in tumour 
cells. Except papillary type adenomas, in the majority 
of pituitary adenoma cases the intensity of the reaction 
was low and moderate, in comparison to the normal tis-
sue (Fig. 3a). 34.2% of S100­positive cases are composed 
of acidophilic cells. Pituitary adenomas with basophilic 
cells represented 26.8% of S100­positive cases, and for 
39 % of cases the chromophobe component was present 
forming pure chromophobe pituitary adenomas or 
mixed chromophobe-acidophilic/basophilic pituitary 
adenomas. 
Regarding the particularities of the immunohis-
tochemical expression of S100 protein, we observed 
variabilities in the presence, the intensity, and the 
distribution of this marker in relation to the hormone 
profile. GH­secreting pituitary adenomas proved to be 
extremely heterogenous in that which considers the 
expression of protein S100 in tumour cells. The cases 
ranged from the absence of its expression in tumour 
cells to a low expression, strictly located in the cyto-
plasm (Fig. 3b), or an intense expression in the entire 
tumour area, nuclear and cytoplasmic, or just cytoplas-
mic (Fig. 3c). In the case of pituitary adenomas with 
chromophobe cells, the expression of S100 protein was 
low in the cytoplasm of the chromophobe cells, being 
mostly nuclear restricted (Fig. 3d).
The particular aspect that we noticed regarding the 
expression of GFAP in ACTH­secreting pituitary adeno-
mas repeated itself in the case of protein S100. Tumour 
cells were negative while, around the vascular spaces, 
S100-positive cells were distributed, having a nuclear 
and cytoplasmic expression, and morphology similar 
to that of GFAP+FS cells. The expansions of the S100+ 
FS cells were strongly attached to the wall of the blood 
vessels, being also interconnected each other. These 
interconnections created a network of S100-positive ex-
pansions amongst which tumour cells were distributed.
As in the case of GH­secreting pituitary adenomas, 
the endothelial cells of the vessels located close to S100- 
-positive cells had a positive reaction for S100 protein 
with a nuclear distribution. In the rest of the tumour 
mass the S100-positive cells with a FS morphology 
were rarely encountered in ACTH­secreting pituitary 
adenomas. 
In relation to the hormone profile, none of the 
six markers used for immunohistochemical profiling 
significantly correlated from a statistical point of view 
with S100 protein expression. Amongst the growth 
factors and corresponding receptors previously stud-
ied by our team, S100 protein significantly correlated 
with EGFR expression in the cases where S100 protein 
presented a moderate or intense expression. 
Discussion
GFAP and S100 protein were studied in pituitary ad-
enomas, being frequently associated with FS cells [21, 
22]. Their expression in tumour cells, separately quanti-
fied in various types of pituitary adenomas, represents 
a sporadic subject in literature and, for this reason, the 
correlations with the prognosis, long-term survival, 
recurrences, and therapeutic implications are extremely 
unconvincing at present. Increasing data suggest the 
ability of tumour endocrine and non-endocrine cells 
to transdifferentiate themselves in FS cells where the 
two markers overlap in that which considers their im-
munohistochemical expression, these FS cells actually 
being considered as pluripotent stem cells [23–25]. The 
‘retrodifferentiation’ phenomenon was observed and 
described especially in the case of ACTH­secreting 
pituitary adenomas [24]. In our study we also ob-
served a particular aspect of distribution, localisation 
and GFAP and S100 expression in the case of ACTH­
secreting pituitary adenomas. FS cells, GFAP+/S100+ 
were distributed around the blood vessels or lined 
pseudovascular spaces. We noticed a slightly increased 
density of these cells through GFAP immunostaining 
compared to protein S100. This discrepancy was sup-
ported by statistical data that showed that only GFAP 
significantly correlated from a statistical point of view 
with the expression of ACTH, while S100 protein did not 
present any statistically significant correlation, despite 
the distribution and morphology concordance. This 
discrepancy of expression suggests two hypotheses: 
(i) the existence of two subpopulations of FS cells, an 
immature one that expresses only S100 with a great 
differentiation capacity and a population of mature FS 
cells GFAP+/S100+ with a well-established role, namely 
to establish the interconnection between the endocrine 
cells and the fenestrated capillary vessels, considering 
their distribution and localisation pre viously described 
correlated with the late expression of GFAP compared 
to S100 protein; and (ii) the existence of the same cell 
population but one that may present more than one 
evolutionary phase. These hypotheses will be demon-
strated or infirmed through the quantification of the 
markers used to show pluripotent stem cells in further 
studies.
As a paradox, the description of S100 protein expres-
sion and that of GFAP in the normal pituitary gland 
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is restricted to the evaluation of FS cells. We have not 
found any data in the literature regarding differential 
GFAP and S100 protein expression in the endocrine 
cells of the normal human pituitary gland.
Nowadays there is an experimental model that sup-
ports the data that we found, regarding the correlation 
between GFAP, ACTH, and LH. This model demon-
strated that the induction of Bmi 1 overexpression by 
GFAP induced, in the experimental murine model, the 
development of pituitary adenomas in the anterior and 
intermediate portions of the adenohypophysis [26]. 
Over 50% of pituitary adenomas overexpress Bmi1 [26], 
a percentage that overlaps with the percentage of GFAP 
+ pituitary adenomas that we found in our study. It has 
been also demonstrated that such pituitary adenomas 
increase ACTH secretion, an aspect that is also in con-
cordance with the data observed and quantified in the 
present study.
The statistically significant association between 
GFAP and VEGF did not come as a surprise, consider-
ing the fact that VEGF was initially isolated from the 
FS cells of bovine adenohypophysis [27] and, moreover, 
pituitary adenomas also expressed VEGF in the tumour 
cells. On the other hand, the lack of association be-
tween VEGF and protein S100 counterbalanced by the 
S100-EGFR association supports the presence of two 
distinct FS cell and adenoma cell populations with 
different functions and having a rather well defined 
prognostic and therapeutic role.
Moreover, S100­EGFR association represents an 
unfavourable prognostic factor that stimulates the 
proliferation, invasion, and metastasis of tumour cells 
in hepatocellular carcinomas [28], glioblastomas [29], 
and melanomas [30]. Pituitary adenomas were not 
characterised from this point of view until now. Our 
data suggest the implication of this mechanism in 
GH­secreting pituitary adenomas and probably in PRL 
secreting ones also, but these data must be validated 
through further studies.
Conclusions
GFAP and protein S100 expression in tumour cells is 
implicated in the pathogenesis of the GH­and PRL­
secreting pituitary adenomas, the mechanisms of activa-
tion being nowadays incompletely studied. This aspect 
seems to represent an unfavourable prognostic factor 
that governs the retro-differentiation phenomenon 
and supports the presence of pluripotent stem cells. 
Our results support the presence of two molecular 
subtypes of FS cells GFAP+/VEGF+/S100 respectively 
and another one that is GFAP-/S100+/EGFR+ simul-
taneously with the classical variant GFAP+/S100+. 
Through analogy with the observations obtained in 
other tumour types, it is possible that S100+/EGFR+ 
pituitary adenomas represent a group of pituitary ad-
enomas with aggressive behaviour and a high ability 
of invasion and recurrence, aspects that represent an 
unfavourable prognostic factor. The GFAP­ACTH­LH 
axis is studied only in experimental models presently, 
but it seems to favour the development of pituitary 
adenomas in the anterior and intermediate regions of 
the adenohypophysis, adenomas that are characterised 
by an unfavourable prognosis. 
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